Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study

  • Satoshi Motoya,
  • Kenji Watanabe,
  • Haruhiko Ogata,
  • Takanori Kanai,
  • Toshiyuki Matsui,
  • Yasuo Suzuki,
  • Mitsuhiro Shikamura,
  • Kenkichi Sugiura,
  • Kazunori Oda,
  • Tetsuharu Hori,
  • Takahiro Araki,
  • Mamoru Watanabe,
  • Toshifumi Hibi
  • Article
  • Metrics
  • Comments
  • Media Coverage

Notice of Republication

An incorrect version of S2 File was published in error. This article was republished on April 2, 2019 to correct for this error. Please download this article again to view the correct version.

Reference

  1. 1. Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, et al. (2019) Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE 14(2): e0212989. https://doi.org/10.1371/journal.pone.0212989

Citation: Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, et al. (2019) Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE 14(4): e0215491. https://doi.org/10.1371/journal.pone.0215491

Published: April 11, 2019

Copyright: © 2019 Motoya et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.